Deep Brain Stimulation (DBS)

What it is

Deep brain stimulation is the most invasive and most precisely targeted intervention in this series: electrodes are surgically implanted into specific deep brain structures and connected to an implanted pulse generator that delivers continuous high-frequency stimulation — in effect, a pacemaker for a dysfunctional neural circuit. DBS is well established and FDA-approved in movement disorders (Parkinson's disease, essential tremor, dystonia), which is both its proof of principle and the source of its psychiatric rationale: if a circuit can be identified, it can in principle be reached and modulated. In psychiatry, DBS remains investigational for depression and operates under a narrow Humanitarian Device Exemption for obsessive-compulsive disorder. It is also the modality whose clinical-trial history most sharply poses the question this series keeps returning to — what does it mean when open-label results are striking but the controlled trials fail?

How it works

DBS does not lesion tissue; it modulates the activity of a pathological circuit, and the effect is reversible and adjustable — stimulation parameters can be tuned, and the device can be turned off. The mechanism is best understood as network modulation: high-frequency stimulation at a node disrupts pathological oscillatory activity and normalizes activity across the connected network rather than simply "activating" or "inhibiting" a single region.

The targets reflect competing hypotheses about depression's circuit anatomy. The subgenual cingulate (Area 25 / Cg25), the target pioneered by Mayberg, was chosen because it is hyperactive in depression and normalizes with recovery — the same structure that anchors the neuroimaging biomarker literature and that TMS reaches indirectly from the cortical surface. Other targets include the ventral capsule/ventral striatum (VC/VS), the medial forebrain bundle (MFB) (Schlaepfer), the nucleus accumbens, and the lateral habenula — each implicating a different node of the reward and limbic circuitry described across this library's dopaminergic and DMN accounts.

The evidence: the open-label/controlled-trial gap

The DBS-for-depression story is the most dramatic instance in this series of a recurring pattern. Early open-label studies were genuinely exciting: Mayberg and colleagues (2005) reported sustained response in treatment-resistant patients with subgenual cingulate stimulation, and subsequent open series at multiple targets reported response rates that, in patients who had failed everything, seemed remarkable.

The randomized sham-controlled trials then failed. The BROADEN trial (subcallosal cingulate DBS) was halted early for futility after a prespecified interim analysis suggested it was unlikely to meet its six-month primary endpoint. The RECLAIM trial (VC/VS DBS, Dougherty and colleagues, 2015) likewise did not separate active from sham on its primary outcome. On the strength of the controlled evidence alone, DBS for depression does not work.

Yet the story does not end there, and this is what makes it instructive. The long-term, open-label follow-up of the BROADEN cohort (Holtzheimer and colleagues, 2017) found that response accrued over time, with substantial proportions responding at one and two years — a time course the six-month blinded endpoint could not capture. Long-term subgenual cingulate data (Crowell and colleagues, 2019) similarly described durable response in those who responded. The interpretive options mirror those for VNS: either the controlled trials correctly showed no effect and the open-label data reflect expectancy and natural course, or the trials were defeated by short endpoints, heterogeneous targeting, and the difficulty of sham-controlling a brain implant. The field has largely concluded that targeting was a central problem — that hitting an anatomically named region is not the same as engaging the right circuit in a given individual.

The new direction: connectomic and closed-loop DBS

This conclusion has reshaped the field. Rather than aiming at a named structure, connectomic targeting uses individual tractography to place electrodes on the specific white-matter bundles whose stimulation predicts response (Riva-Posse and colleagues), turning DBS into a personalized, biomarker-guided procedure. The most striking recent advance is closed-loop (adaptive) DBS: Scangos and colleagues (2021) identified a personalized neural biomarker of the depressed state in an individual patient and built a device that delivered stimulation only when that biomarker appeared — a landmark single-case demonstration linking the electrophysiology biomarker program directly to responsive treatment. These approaches are early and not yet validated at scale, but they reframe DBS's trial failures as failures of one-size-fits-all targeting rather than of the underlying premise.

Indications

The one approved psychiatric indication is treatment-refractory OCD, under a Humanitarian Device Exemption (VC/VS target), where response rates in carefully selected, extremely refractory patients are meaningful (Greenberg, Denys, and colleagues). For depression, DBS remains strictly investigational, reserved for research protocols in the most severe, treatment-resistant cases. It is never a routine option.

Practical considerations

DBS carries genuine surgical risk: intracranial hemorrhage (on the order of 1–2%), infection, and hardware complications, alongside stimulation-induced effects that can include hypomania, anxiety, or transient mood shifts. Its compensating advantage over ablative approaches is that the intervention is reversible and tunable — if stimulation produces an adverse effect, parameters can be adjusted or the device deactivated. It is an enormous undertaking reserved for the most refractory illness.

The convergence

DBS sits at the extreme invasive, maximally targeted end of the interventional spectrum. It targets the same subgenual cingulate that defines the neuroimaging biomarker literature and that TMS reaches non-invasively, and the same ventral striatal reward circuitry implicated in anhedonia. Its frontier — closed-loop stimulation triggered by a neural biomarker — is the most literal fusion of the diagnostics and interventional programs anywhere in this library: a biomarker that not only predicts but actively gates treatment.

Caveats — load-bearing, not decorative

The central caveat is the controlled-evidence gap: the randomized trials of DBS for depression failed their primary endpoints, and the affirmative case rests on open-label data vulnerable to expectancy and natural-course confounds. Second, invasiveness and risk confine DBS to the most extreme cases and demand stringent ethical oversight. Third, the connectomic and closed-loop advances, though conceptually compelling, rest so far on small samples and single cases; they are reasons for hope, not yet evidence of efficacy. The honest summary is that DBS for depression is a promising, mechanistically rich research program whose controlled efficacy is unproven, and whose future likely depends on solving the targeting problem.

Bottom line

DBS is the most invasive and most precisely targeted intervention in psychiatry, approved (under humanitarian exemption) only for refractory OCD and otherwise investigational for depression. Its controlled trials for depression failed, but its long-term open-label data and its pivot toward individualized connectomic and closed-loop targeting keep it a serious research enterprise rather than a dead end. It best illustrates two of this series' themes at once: the danger of reading open-label enthusiasm as proof, and the promise of fusing biomarkers with intervention — nowhere more literally than in a device that stimulates only when it detects the depressed brain state. For now it belongs to research protocols and the most refractory patients, with realistic expectations and rigorous oversight.

Selected references

1. Mayberg HS, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005.
2. Lozano AM, et al. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry. 2008.
3. Holtzheimer PE, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry. 2012.
4. Holtzheimer PE, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial (BROADEN). Lancet Psychiatry. 2017.
5. Dougherty DD, et al. A randomized sham-controlled trial of DBS of the ventral capsule/ventral striatum for chronic treatment-resistant depression (RECLAIM). Biol Psychiatry. 2015.
6. Schlaepfer TE, et al. Rapid effects of deep brain stimulation for treatment-resistant major depression (medial forebrain bundle). Biol Psychiatry. 2013.
7. Malone DA, et al. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry. 2009.
8. Crowell AL, et al. Long-term outcomes of subcallosal cingulate deep brain stimulation for treatment-resistant depression. Am J Psychiatry. 2019.
9. Riva-Posse P, et al. A connectomic approach for subcallosal cingulate deep brain stimulation surgery. Mol Psychiatry. 2018.
10. Scangos KW, et al. Closed-loop neuromodulation in an individual with treatment-resistant depression. Nat Med. 2021.
11. Greenberg BD, et al. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry. 2010.
12. Denys D, et al. Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2010.
13. Bergfeld IO, et al. Deep brain stimulation of the ventral anterior limb of the internal capsule for treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2016.
14. Figee M, et al. Deep brain stimulation for depression. Neurotherapeutics. 2022.
15. Drobisz D, Damborská A. Deep brain stimulation targets for treating depression. Behav Brain Res. 2019.
16. Mayberg HS. Targeted electrode-based modulation of neural circuits for depression. J Clin Invest. 2009.
17. Dougherty DD. Deep brain stimulation: clinical applications. Psychiatr Clin North Am. 2018.
18. Widge AS, et al. Deep brain stimulation for treatment-resistant psychiatric illnesses: what has gone wrong and what should we do next? Biol Psychiatry. 2016.
19. Sheth SA, Mayberg HS. Deep brain stimulation for obsessive-compulsive disorder and depression. Annu Rev Neurosci. 2023.
20. Provenza NR, et al. Long-term ecological assessment of intracranial electrophysiology coupled to behavioral indices in OCD. Nat Med. 2021.